A new therapeutic approach for LS-SCLC includes the combination of an anti-TGIT monoclonal antibody with immune checkpoint inhibitors, such as anti-PD-L1, anti-PD1, and anti-CTLA4 antibodies. Here, CD274 is linked to small cell lung carcinoma.